US FDA Approves RINVOQ^® (Upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn’s Disease in Adults

AbbVie announced that the US FDA has approved RINVOQ® for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers.